Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Laboratorios Phoenix SA

Division of GlaxoSmithKline PLC

Latest From Laboratorios Phoenix SA

2011 Scrip 100: Re-engineering Roche

Roche is overhauling its cost structure to produce a leaner organisation better equipped to focus on the business of pharmaceutical innovation. It is also investing heavily in China, turning its Shanghai operations into a centre for everything from commercial manufacturing and research to partnering, licensing and strategic planning. Pascal Soriot, chief operating officer of Roche Pharmaceuticals, speaks to Pete Chan in an exclusive interview.

Metabolic Disorders Cancer

2011 Scrip 100: GSK goes back to return on investment

Flagging investor confidence in the traditional pharmaceutical model in the years following its mega-merger convinced GlaxoSmithKline that it needed to execute drastic change. Brought into the corporate team to help make it happen, chief strategy officer David Redfern tells Elizabeth Sukkar how a more aggressive approach has refocused GSK on R&D metrics that deliver true value.

Metabolic Disorders Gastrointestinal

Pharma: Serious About Change?

Pharmaceutical companies are attempting to solve unprecedented R&D and commercial challenges via business development, emphasizing cheaper, earlier-stage alliances and building up a base in emerging markets. An analysis of dealmaking trends from 2007 to 2010 shows big companies are embracing new kinds of partners, and shifting away from historic areas of interest to pursue hyper-specialty products and generics.

BioPharmaceutical Research and Development Strategies

2010 Scrip 100 - Pharma muscles into emerging markets with M&A

This year has seen many firms facing patent expiries on core revenue generators. The current climate is driving M&A strategies, particularly in emerging markets and often with a focus on branded generics. Abbott has used M&A to propel itself to the top of the Indian market, writes Karen Beynon.

Cardiovascular Dermatology
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • Nutraceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • South America
      • Argentina
  • Parent & Subsidiaries
  • GlaxoSmithKline PLC
  • Senior Management
  • Contact Info
  • Laboratorios Phoenix SA
    Phone: (54) 11 4379 4200
    1192 Humahuaca
    Buenos Aires, 4065